Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To demonstrate that secukinumab has superior efficacy compared to placebo on the pruritus intensity VAS (the worst itching within a recall period of 24 hours as part of the Patients Global Assessment of Chronic Pruritus, PGA-CP) measured at week 32 in patients with moderate to severe psoriasis.
Critère d'inclusion
- chronic moderate to severe plaque type psoriasis